Fig 1: IRF4 overexpression inhibits osteogenic differentiation of BM-MSCs via miR-636/DOCK9. (A) Western blotting was performed to detect DOCK9 expression. ARS (B) and ALP (C) staining assays were performed to determine osteogenic differentiation. Osteogenic differentiation biomarkers were determined by Western blotting (D). *p < 0.05. Data represent at least three independent sets of experiments.
Fig 2: miR-636 binds to the 3'-UTR of DOCK9. The miRDB database and GSE18043 dataset were used to identify the target genes of miR-636 (A), and Western blotting and q-PCR were performed to detect the expression of intersected genes (B). q-PCR results showed the expression of DOCK9 in BM-MSCs (C). BM-MSCs with overexpression or reduced expression of miR-636 were constructed, and q-PCR (D) and Western blotting (E) were respectively utilized to examine the transfection efficacy and DOCK9 expression. Dual Luciferase Reporter (F) and RIP (G) assays were applied to elaborate the relationship between miR-636 and DOCK9. *p < 0.05. Data represent at least three independent sets of experiments.
Supplier Page from Abcam for Anti-DOCK9/Trg antibody